Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines
1996
Aclarubicin's Effectiveness Against Drug-Resistant Liver Cancer Cells
publication
Evidence: moderate
Author Information
Author(s): G Lehne, P De Angelis, OPF Clausen, HE Rugstad
Primary Institution: The National Hospital, Rikshospitalet, Oslo, Norway
Hypothesis
Can aclarubicin retain its effectiveness in human hepatoma cells that overexpress P-glycoprotein?
Conclusion
Aclarubicin remains effective in multidrug-resistant human hepatoma cells, unlike other anthracyclines.
Supporting Evidence
- Aclarubicin was effective in inhibiting cell growth in resistant hepatoma cells.
- Other anthracyclines showed high resistance in the same cell line.
- SDZ PSC 833 enhanced the effectiveness of other anthracyclines but not aclarubicin.
Takeaway
Aclarubicin is a special medicine that can still work against certain cancer cells that usually resist treatment.
Methodology
The study compared the effects of four anthracyclines on human hepatoma cell lines with different levels of P-glycoprotein.
Limitations
The study was conducted in vitro, and results may not fully translate to clinical settings.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website